Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. registered with the SEC in 2024 as a blank-check company purpose-built to acquire a domestic pharmaceutical or biotechnology manufacturing business. The sponsor group is anonymous in early filings — no named CEO or CFO appears in the initial S-1 — a structure common among pre-pricing SPACs where the management team is finalized closer to the roadshow. The vehicle targets a single US-based operating company, with the stated policy objective of reducing American dependence on foreign active pharmaceutical ingredient (API) and finished-dose production. The SPAC intends to focus on firms operating FDA-registered facilities within the United States, spanning generic drug manufacturing, sterile injectables, API production, and advanced biologics capacity. The $200 million trust — standard for a micro-to-mid-cap SPAC — would target an enterprise value between $800 million and $1.5 billion once a business combination is announced, depending on PIPE financing and redemptions. The fund-raising thesis leverages the CHIPS and Science Act-era sentiment for reshoring critical supply chains, explicitly citing the national-security dimension of pharmaceutical self-sufficiency. The vehicle has no reported team size, no disclosed prior deals, and no announced target as of mid-2024. It is one of a handful of policy-themed SPACs that emerged in the post-ZIRP window, following precedents like ESG-focused or energy-transition blank-check companies. The SPAC is domiciled in Delaware and lists a Sarasota, Florida address on SEC filings. No parallel philanthropic or operating entities are publicly associated with the sponsor. Unlike most SPACs formed by repeat sponsors or celebrity investors, Drugs Made In America Acquisition Corp. is structurally distinguished by its single-policy mandate: the entire investment thesis is a regulatory arbitrage on reshoring tailwinds rather than a generalist tech or consumer growth strategy. This narrow aperture may accelerate a de-SPAC timeline if the sponsor group has pre-identified targets — or stall the vehicle indefinitely if no qualifying asset meets the domestic-manufacturing criteria at an acceptable multiple.